FDA approves Gilead’s Hepcludex as the first treatment for chronic hepatitis delta virus in the U.S., marking a major ...
In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA ...
Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall ...
Surpass-Early randomized ~800 adults with ≤4-year type 2 diabetes on metformin to add tirzepatide or intensify care, predominantly with semaglutide or dulaglutide comparators. At two years, ...
WHO identifies experimental therapies from Mapp Biopharmaceutical, Regeneron, and Gilead as leading candidates for the Bundibugyo strain of Ebola virus disease, as the agency pushes for urgent ...
Zepbound’s return as a preferred option reverses a prior formulary exclusion that maintained Wegovy coverage, underscoring how net pricing and rebate contracting drive PBM obesity access decisions.
Eli Lilly enters three separate acquisitions totaling $3.83 billion in a push into vaccines and infectious diseases, signaling a strategic expansion into prevention-focused medicines. Eli Lilly ...
VRBPAC is evaluating an XFG-targeted composition for 2026–2027 vaccines, based on CDC variant prevalence estimates that are more than a month old. FDA briefing materials emphasize eroding sequencing ...
The Incyte–Genesis deal pairs significant upfront capital with long-tail milestones and royalties, while granting Incyte ...
In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s ...
Sales concentration follows a Pareto dynamic, but the exceptionally large eligible GLP-1 population inflates risk-adjusted ...
Talent and leadership culture convert finance into a strategic asset, emphasizing judgment under uncertainty and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results